These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2186417)

  • 21. Animal test systems to study behavioral dysfunctions of neurodegenerative disorders.
    Anger WK
    Neurotoxicology; 1991; 12(3):403-13. PubMed ID: 1745432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The canine model of human cognitive aging and dementia: pharmacological validity of the model for assessment of human cognitive-enhancing drugs.
    Studzinski CM; Araujo JA; Milgram NW
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Mar; 29(3):489-98. PubMed ID: 15795058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NGF and the treatment of Alzheimer's disease.
    Olson L
    Exp Neurol; 1993 Nov; 124(1):5-15. PubMed ID: 8282080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.
    Decker MW; Brioni JD; Sullivan JP; Buckley MJ; Radek RJ; Raszkiewicz JL; Kang CH; Kim DJ; Giardina WJ; Wasicak JT
    J Pharmacol Exp Ther; 1994 Jul; 270(1):319-28. PubMed ID: 7913497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. On the trail of a cognitive enhancer for the treatment of schizophrenia.
    Stip E; Chouinard S; Boulay LJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):219-32. PubMed ID: 15694228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological mechanisms and animal models of cognition.
    Dawson GR; Heyes CM; Iversen SD
    Behav Pharmacol; 1992 Aug; 3(4):285-297. PubMed ID: 11224129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different behaviors and different strains: potential new ways to model bipolar disorder.
    Einat H
    Neurosci Biobehav Rev; 2007; 31(6):850-7. PubMed ID: 17307253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of one Chinese herbs on improving cognitive function and memory of Alzheimer's disease mouse models].
    Sun H; Hu Y; Zhang JM; Li SY; He W
    Zhongguo Zhong Yao Za Zhi; 2003 Aug; 28(8):751-4. PubMed ID: 15015359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Research design issues: antialuminum drug studies in Alzheimer's disease.
    Shore D; Wyatt RJ
    Clin Neuropharmacol; 1982 Dec; 5(4):337-43. PubMed ID: 7159877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia.
    Floresco SB; Geyer MA; Gold LH; Grace AA
    Schizophr Bull; 2005 Oct; 31(4):888-94. PubMed ID: 16079387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measuring cognitive change in Alzheimer's disease clinical drug trials.
    Harrison JE
    J Nutr Health Aging; 2007; 11(4):327-9. PubMed ID: 17653492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New therapeutic approaches to Alzheimer's disease.
    Schneider LS
    J Clin Psychiatry; 1996; 57 Suppl 14():30-6. PubMed ID: 9024334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive enhancing agents: current status in the treatment of Alzheimer's disease.
    Waters C
    Can J Neurol Sci; 1988 Aug; 15(3):249-56. PubMed ID: 3061625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The families of cognition enhancers.
    Fröstl W; Maître L
    Pharmacopsychiatry; 1989 Oct; 22 Suppl 2():54-100. PubMed ID: 2690152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cognitive neuropharmacology: new perspectives for the pharmacology of cognition.
    Le Merrer J; Noguès X
    Pharmacol Res; 2000 May; 41(5):503-14. PubMed ID: 10753548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I.
    Sarter M; Hagan J; Dudchenko P
    Psychopharmacology (Berl); 1992; 107(2-3):144-59. PubMed ID: 1615119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of EEG parameters as predictors of drug effects on cognition.
    Blokland A; Prickaerts J; van Duinen M; Sambeth A
    Eur J Pharmacol; 2015 Jul; 759():163-8. PubMed ID: 25823806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human cognition assessment in drug research.
    Riedel WJ; Mehta MA; Unema PJ
    Curr Pharm Des; 2006; 12(20):2525-39. PubMed ID: 16842175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical psychopharmacology of AIDS-associated dementia: lessons to be learned from the cognitive psychopharmacology of other dementias.
    Sarter M; Podell M
    J Psychopharmacol; 2000; 14(3):197-204. PubMed ID: 11106297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.